Ascendis Pharma A/S (ASND) Financials

$161.57 +1.24 (+0.77%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for Ascendis Pharma A/S

This table shows Ascendis Pharma A/S's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-391	-533	-624	-434	-512	-245	-149	-149	-72	-36
Consolidated Net Income / (Loss)	-391	-533	-624	-434	-512	-245	-149	-149	-72	-36
Net Income / (Loss) Continuing Operations	-391	-533	-624	-434	-512	-245	-149	-149	-72	-36
Total Pre-Tax Income	-386	-524	-618	-435	-512	-245	-149	-149	-72	-36
Total Operating Income	-289	-504	-601	-511	-404	-254	-177	-134	-77	-45
Total Gross Profit	331	246	42	4.82	8.49	15	12	1.84	4.85	8.82
Total Revenue	376	295	55	8.80	8.49	15	12	1.84	4.85	8.82
Operating Revenue	376	295	55	8.80	8.49	15	12	1.84	4.85	8.82
Total Cost of Revenue	46	49	13	3.99	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cost of Revenue	46	49	13	3.99	0.00	0.00	-	-	-	-
Total Operating Expenses	619	750	643	516	412	269	189	136	82	54
Selling, General & Admin Expense	301	292	237	181	94	54	29	16	12	10
Research & Development Expense	318	457	406	335	319	215	161	120	69	44
Total Other Income / (Expense), net	-98	-21	-17	77	-108	9.50	28	-15	4.41	8.97
Interest Expense	104	49	54	4.43	99	1.37	0.15	17	3.27	3.04
Interest & Investment Income	27	49	56	68	2.21	20	28	1.11	7.68	12
Other Income / (Expense), net	-21	-20	-19	14	-12	-9.10	-0.37	0.00	0.00	-
Income Tax Expense	5.01	8.08	5.75	-0.42	-0.27	-0.26	-0.45	-0.57	-0.24	-0.71
Basic Earnings per Share	($6.76)	($9.46)	($11.13)	($7.00)	-	-	($3.17)	($3.68)	($2.58)	($1.39)
Weighted Average Basic Shares Outstanding	57.89M	56.29M	56.07M	54.77M	50.62M	46.51M	41.09M	33.63M	26.56M	23.77M
Diluted Earnings per Share	($6.76)	($9.46)	($11.13)	($7.00)	-	-	($3.17)	($3.68)	($2.58)	($1.39)
Weighted Average Diluted Shares Outstanding	60.69M	57.71M	57.15M	56.94M	50.62M	52.19M	41.09M	38.00M	26.56M	23.77M
Weighted Average Basic & Diluted Shares Outstanding	60.69M	57.71M	57.15M	56.94M	50.62M	52.19M	41.09M	38.00M	26.56M	-

No quarterly income statements for Ascendis Pharma A/S are available.

This table details how cash moves in and out of Ascendis Pharma A/S's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	150	-52	-40	-200	49	351	71	34	60	67
Net Cash From Operating Activities	-298	-517	-530	-473	-332	-197	-159	-114	-63	-47
Net Cash From Continuing Operating Activities	-298	-514	-528	-476	-327	-195	-146	-113	-63	-47
Net Income / (Loss) Continuing Operations	0.00	-533	-624	-434	-512	-245	-149	-149	-72	-36
Non-Cash Adjustments To Reconcile Net Income	-292	129	92	51	174	44	-0.83	28	3.43	-7.10
Changes in Operating Assets and Liabilities, net	-5.71	-131	-15	-110	-1.68	-1.90	3.15	6.87	4.86	-4.92
Net Cash From Investing Activities	-0.49	317	66	-125	-356	-5.79	-3.03	-1.13	-0.71	-1.13
Net Cash From Continuing Investing Activities	-0.49	320	71	-125	-362	-5.79	-3.03	-1.13	-0.71	-1.13
Purchase of Property, Plant & Equipment	-1.48	-	-	-27	-24	-5.79	-3.03	-1.13	-0.71	-1.13
Sale of Property, Plant & Equipment	0.98	0.06	0.00	0.00	-	-	-	-	-	-
Sale and/or Maturity of Investments	0.00	320	300	170	321	0.00	0.00	-	-	-
Net Cash From Financing Activities	448	149	424	398	736	554	233	150	124	115
Net Cash From Continuing Financing Activities	448	151	424	398	736	554	233	150	124	115
Repayment of Debt	-12	-12	-6.80	-7.28	-5.83	-4.53	0.00	0.00	-	-
Repurchase of Common Equity	0.00	0.00	-113	-24	0.00	0.00	-15	-10	-8.95	-9.12
Issuance of Debt	139	151	538	0.00	-	-	-	-	-	-0.14
Issuance of Common Equity	321	0.00	0.00	416	709	539	248	160	133	124

No quarterly cash flow statements for Ascendis Pharma A/S are available.

This table presents Ascendis Pharma A/S's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016
Period end date	12/31/2024	12/31/2023	1/1/2023	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016
Total Assets	1,221	913	1,166	1,228	1,197	759	365	253	200
Total Current Assets	1,069	727	955	885	904	686	335	238	190
Cash & Equivalents	579	434	476	505	714	671	318	235	190
Accounts Receivable	182	61	29	27	11	7.72	2.04	1.92	-
Inventories, net	306	231	140	85	0.00	-	-	-	-
Current Deferred & Refundable Income Taxes	1.84	0.89	-	-	-	-	0.97	0.93	0.78
Plant, Property, & Equipment, net	-0.45	86	130	141	132	51	4.95	3.07	2.47
Plant, Property & Equipment, gross	-0.45	86	130	141	132	51	4.95	3.07	-4.58
Total Noncurrent Assets	46	51	72	200	469	104	39	13	12
Long-Term Investments	14	6.29	33	165	152	17	20	0.00	-
Noncurrent Note & Lease Receivables	2.40	2.35	-	-	-	-	-	-	-
Other Noncurrent Operating Assets	29	43	34	29	310	82	16	8.65	8.49
Total Liabilities & Shareholders' Equity	920	696	1,166	1,228	1,197	759	365	253	200
Total Liabilities	1,330	1,074	884	228	172	89	45	29	14
Total Current Liabilities	102	108	108	70	27	32	45	29	14
Accounts Payable	100	105	108	67	27	31	37	29	14
Current Deferred & Payable Income Tax Liabilities	1.26	2.54	-	-	-	0.13	0.01	0.00	-
Other Current Liabilities	0.97	1.31	-	2.94	0.44	0.96	7.90	0.00	-
Total Noncurrent Liabilities	928	749	767	155	145	57	0.00	0.00	0.10
Long-Term Debt	852	697	544	119	-	-	-	-	-
Other Noncurrent Operating Liabilities	76	52	218	37	32	16	-	-	-
Total Equity & Noncontrolling Interests	-109	-161	282	1,000	1,025	670	321	225	186
Total Preferred & Common Equity	-109	-161	282	1,000	1,025	670	321	225	186
Total Common Equity	-109	-161	282	1,000	1,025	670	321	225	186
Common Stock	8.44	8.57	8.21	8.65	8.82	7.23	6.48	5.97	-
Other Equity Adjustments	-118	-170	274	991	1,016	663	314	219	186

No quarterly balance sheets for Ascendis Pharma A/S are available.

This table displays calculated financial ratios and metrics derived from Ascendis Pharma A/S's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	27.58%	438.93%	521.89%	3.64%	-43.41%	23.95%	558.91%	-62.07%	-45.07%	0.00%
EBITDA Growth	38.55%	16.21%	-25.08%	-18.89%	-57.78%	-45.08%	-32.59%	-75.14%	-69.50%	0.00%
EBIT Growth	41.00%	15.44%	-24.56%	-19.78%	-57.67%	-48.48%	-32.47%	-74.66%	-68.80%	0.00%
NOPAT Growth	42.74%	16.16%	-17.54%	-26.60%	-58.74%	-43.65%	-32.19%	-74.66%	-68.80%	0.00%
Net Income Growth	26.52%	14.64%	-43.71%	15.18%	-109.18%	-64.32%	-0.04%	-106.52%	-101.47%	0.00%
EPS Growth	28.53%	14.99%	-58.94%	0.00%	0.00%	0.00%	13.86%	-42.64%	-85.61%	0.00%
Operating Cash Flow Growth	42.41%	2.51%	-12.19%	-42.50%	-68.01%	-24.29%	-39.06%	-80.45%	-34.05%	0.00%
Free Cash Flow Firm Growth	53.79%	-148.77%	-74.94%	76.09%	-101.24%	-149.56%	-41.56%	-49.19%	0.00%	0.00%
Invested Capital Growth	30.33%	4,112.33%	-96.56%	-54.50%	315.68%	663.87%	-74.34%	-724.65%	0.00%	0.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	87.83%	83.36%	76.28%	54.71%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-82.18%	-170.60%	-1,097.34%	-5,455.90%	-4,756.16%	-1,705.74%	-1,457.31%	-7,242.29%	-1,568.45%	-508.34%
Operating Margin	-76.66%	-170.80%	-1,097.85%	-5,808.59%	-4,755.07%	-1,695.10%	-1,462.59%	-7,290.26%	-1,583.15%	-515.21%
EBIT Margin	-82.18%	-177.69%	-1,132.43%	-5,653.78%	-4,892.05%	-1,755.75%	-1,465.63%	-7,290.26%	-1,583.15%	-515.21%
Profit (Net Income) Margin	-103.97%	-180.51%	-1,139.63%	-4,931.56%	-6,025.53%	-1,630.03%	-1,229.53%	-8,097.84%	-1,487.30%	-405.54%
Tax Burden Percent	101.30%	101.54%	100.93%	99.90%	99.95%	99.89%	99.70%	99.62%	99.67%	98.06%
Interest Burden Percent	124.90%	100.04%	99.71%	87.31%	123.23%	92.94%	84.15%	111.51%	94.26%	80.27%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-66.58%	-261.59%	-447.45%	-123.13%	-114.07%	-450.45%	0.00%	0.00%	-6,860.75%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-109.74%	-502.75%	-410.30%	-112.58%	-75.86%	-435.85%	0.00%	0.00%	-6,840.81%	0.00%
Return on Net Nonoperating Assets (RNNOA)	355.84%	-621.92%	350.11%	80.25%	53.67%	401.06%	0.00%	0.00%	6,783.17%	0.00%
Return on Equity (ROE)	289.26%	-883.51%	-97.35%	-42.88%	-60.40%	-49.40%	-54.60%	-72.48%	-77.58%	0.00%
Cash Return on Invested Capital (CROIC)	-92.91%	-452.31%	-260.76%	-48.21%	-236.50%	-303.02%	0.00%	0.00%	-7,060.75%	0.00%
Operating Return on Assets (OROA)	-28.99%	-50.43%	-51.80%	-41.05%	-42.48%	-46.87%	-57.39%	-59.10%	-38.36%	0.00%
Return on Assets (ROA)	-36.68%	-51.23%	-52.13%	-35.81%	-52.32%	-43.52%	-48.15%	-65.65%	-36.04%	0.00%
Return on Common Equity (ROCE)	289.26%	-883.51%	-97.35%	-42.88%	-60.40%	-49.40%	-54.60%	-72.48%	-77.58%	0.00%
Return on Equity Simple (ROE_SIMPLE)	357.68%	330.44%	-221.45%	-43.41%	-49.95%	-36.51%	-46.45%	-66.18%	-38.79%	0.00%
Net Operating Profit after Tax (NOPAT)	-202	-353	-421	-358	-283	-178	-124	-94	-54	-32
NOPAT Margin	-53.66%	-119.56%	-768.50%	-4,066.01%	-3,328.55%	-1,186.57%	-1,023.82%	-5,103.18%	-1,108.21%	-360.65%
Net Nonoperating Expense Percent (NNEP)	43.17%	241.17%	-37.15%	-10.56%	-38.21%	-14.60%	-8.71%	-26.28%	-19.94%	0.00%
Return On Investment Capital (ROIC_SIMPLE)	-27.19%	-65.83%	-50.96%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	12.17%	16.64%	23.72%	45.29%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	80.06%	99.13%	432.30%	2,059.40%	1,102.68%	362.41%	236.81%	881.18%	249.76%	115.98%
R&D to Revenue	84.43%	155.02%	741.83%	3,803.90%	3,752.39%	1,432.68%	1,325.78%	6,509.08%	1,433.39%	499.24%
Operating Expenses to Revenue	164.49%	254.15%	1,174.13%	5,863.29%	4,855.07%	1,795.10%	1,562.59%	7,390.26%	1,683.15%	615.21%
Earnings before Interest and Taxes (EBIT)	-309	-524	-620	-498	-416	-264	-177	-134	-77	-45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-309	-503	-601	-480	-404	-256	-176	-133	-76	-45
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	24.68	7.23	7.81	8.75	7.23	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	25.14	7.27	7.86	8.80	7.32	0.00	0.00	0.00
Price to Revenue (P/Rev)	21.11	24.40	127.02	821.42	942.22	390.53	191.33	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	23.89	28.30	1,067.84	35.27	17.73	54.24	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	21.79	25.27	121.99	728.46	834.17	347.38	163.46	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-7.79	-4.32	1.93	0.12	0.11	0.06	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	-7.79	-4.32	1.93	0.12	0.11	0.06	0.00	0.00	0.00	0.00
Financial Leverage	-3.24	1.24	-0.85	-0.71	-0.71	-0.92	-1.05	-1.02	-0.99	0.00
Leverage Ratio	-7.89	17.25	1.87	1.20	1.15	1.14	1.13	1.10	1.08	0.00
Compound Leverage Factor	-9.85	17.25	1.86	1.05	1.42	1.06	0.95	1.23	1.01	0.00
Debt to Total Capital	114.73%	130.08%	65.88%	10.62%	9.88%	5.78%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	114.73%	130.08%	65.88%	10.62%	9.88%	5.78%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-14.73%	-30.08%	34.12%	89.38%	90.12%	94.22%	100.00%	100.00%	100.00%	0.00%
Debt to EBITDA	-2.76	-1.38	-0.91	-0.25	-0.28	-0.16	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-0.84	-0.51	0.46	1.70	2.27	2.53	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-2.76	-1.38	-0.91	-0.25	-0.28	-0.16	0.00	0.00	0.00	0.00
Debt to NOPAT	-4.22	-1.98	-1.29	-0.33	-0.40	-0.23	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-1.28	-0.73	0.65	2.29	3.25	3.64	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-4.22	-1.98	-1.29	-0.33	-0.40	-0.23	0.00	0.00	0.00	0.00
Altman Z-Score	4.01	3.26	3.88	18.51	27.60	39.27	30.60	0.00	0.00	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	10.48	6.70	8.84	12.60	33.25	21.26	7.53	8.32	13.85	0.00
Quick Ratio	7.46	4.56	7.54	11.39	32.68	21.05	7.19	8.29	13.79	0.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-282	-610	-245	-140	-586	-291	-117	-82	-55	0.00
Operating Cash Flow to CapEx	-60,297.87%	0.00%	0.00%	-1,761.93%	-1,367.31%	-3,410.27%	-5,241.77%	-10,106.16%	-8,955.21%	-4,183.45%
Free Cash Flow to Firm to Interest Expense	-2.72	-12.51	-4.54	-31.66	-5.94	-212.57	-802.98	-4.99	-16.88	0.00
Operating Cash Flow to Interest Expense	-2.88	-10.61	-9.82	-106.79	-3.36	-144.09	-1,092.93	-6.91	-19.34	-15.54
Operating Cash Flow Less CapEx to Interest Expense	-2.88	-10.61	-9.82	-112.85	-3.60	-148.32	-1,113.78	-6.98	-19.55	-15.91
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.35	0.28	0.05	0.01	0.01	0.03	0.04	0.01	0.02	0.00
Accounts Receivable Turnover	3.10	6.61	1.96	0.46	0.92	3.08	6.12	0.00	0.00	0.00
Inventory Turnover	0.17	0.26	0.12	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	2.73	0.40	0.06	0.09	0.54	3.02	0.66	1.96	0.00
Accounts Payable Turnover	0.45	0.46	0.15	0.08	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	117.64	55.26	186.02	786.31	394.66	118.61	59.65	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	2,139.67	1,378.38	3,164.44	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	814.22	790.40	2,464.40	4,302.27	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	1,443.10	643.23	886.06	-3,515.96	394.66	118.61	59.65	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	343	263	6.25	182	400	96	-17	-9.78	1.57	0.00
Invested Capital Turnover	1.24	2.19	0.58	0.03	0.03	0.38	-0.90	-0.45	6.19	0.00
Increase / (Decrease) in Invested Capital	80	257	-176	-218	303	113	-7.27	-11	1.57	0.00
Enterprise Value (EV)	8,204	7,455	6,678	6,413	7,085	5,214	1,979	0.00	0.00	0.00
Market Capitalization	7,945	7,198	6,954	7,231	8,003	5,862	2,317	0.00	0.00	0.00
Book Value per Share	($1.90)	($2.82)	$4.95	$18.61	$21.35	$15.90	$8.67	$6.69	$6.99	$0.00
Tangible Book Value per Share	($1.90)	($2.82)	$4.86	$18.50	$21.21	$15.81	$8.56	$6.56	$6.86	$0.00
Total Capital	743	536	826	1,119	1,137	711	321	225	186	0.00
Total Debt	852	697	544	119	112	41	0.00	0.00	0.00	0.00
Total Long-Term Debt	852	697	544	119	112	41	0.00	0.00	0.00	0.00
Net Debt	259	257	-275	-818	-918	-648	-338	-235	-190	0.00
Capital Expenditures (CapEx)	0.49	-0.06	0.00	27	24	5.79	3.03	1.13	0.71	1.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)	388	184	60	42	-1.13	-18	-27	-26	-13	0.00
Debt-free Net Working Capital (DFNWC)	967	618	847	814	877	654	291	209	177	0.00
Net Working Capital (NWC)	967	618	847	814	877	654	291	209	177	0.00
Net Nonoperating Expense (NNE)	189	180	203	76	229	67	25	55	18	3.96
Net Nonoperating Obligations (NNO)	453	425	-275	-818	-625	-574	-338	-235	-184	0.00
Total Depreciation and Amortization (D&A)	0.00	21	19	17	12	7.51	1.01	0.88	0.71	0.61
Debt-free, Cash-free Net Working Capital to Revenue	102.99%	62.48%	110.02%	481.97%	-13.26%	-117.24%	-225.62%	-1,398.17%	-267.87%	0.00%
Debt-free Net Working Capital to Revenue	256.86%	209.52%	1,547.19%	9,251.12%	10,324.65%	4,354.58%	2,400.43%	11,369.87%	3,647.22%	0.00%
Net Working Capital to Revenue	256.86%	209.52%	1,547.19%	9,251.12%	10,324.65%	4,354.58%	2,400.43%	11,369.87%	3,647.22%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($6.76)	($8.55)	$0.00	$0.00	($8.28)	($4.69)	($3.17)	($3.68)	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	57.89M	56.29M	56.07M	54.77M	50.62M	46.51M	41.09M	33.63M	0.00	0.00
Adjusted Diluted Earnings per Share	($6.76)	($8.55)	$0.00	$0.00	($8.28)	($4.69)	($3.17)	($3.68)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	60.69M	57.71M	57.15M	56.94M	53.75M	47.99M	42.14M	33.63M	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	($8.55)	$0.00	$0.00	($8.28)	($4.69)	($3.17)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	60.69M	57.71M	57.15M	56.94M	53.75M	47.99M	42.14M	36.98M	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-202	-353	-421	-358	-283	-178	-124	-94	-54	-32
Normalized NOPAT Margin	-53.66%	-119.56%	-768.50%	-4,066.01%	-3,328.55%	-1,186.57%	-1,023.82%	-5,103.18%	-1,108.21%	-360.65%
Pre Tax Income Margin	-102.64%	-177.77%	-1,129.12%	-4,936.28%	-6,028.68%	-1,631.78%	-1,233.26%	-8,129.02%	-1,492.23%	-413.57%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2.99	-10.76	-11.48	-112.44	-4.21	-192.33	-1,221.08	-8.11	-23.43	-14.95
NOPAT to Interest Expense	-1.95	-7.24	-7.79	-80.86	-2.86	-129.98	-852.99	-5.68	-16.40	-10.47
EBIT Less CapEx to Interest Expense	-2.99	-10.75	-11.48	-118.50	-4.45	-196.55	-1,241.94	-8.18	-23.65	-15.33
NOPAT Less CapEx to Interest Expense	-1.96	-7.24	-7.79	-86.92	-3.11	-134.20	-873.84	-5.74	-16.62	-10.84
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	-18.06%	-5.63%	0.00%	0.00%	-10.08%	-6.77%	-12.41%	-25.50%

No quarterly metrics and ratios for Ascendis Pharma A/S are available.

Frequently Asked Questions About Ascendis Pharma A/S's Financials

When does Ascendis Pharma A/S's fiscal year end?

According to the most recent income statement we have on file, Ascendis Pharma A/S's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Ascendis Pharma A/S's net income changed over the last 9 years?

Ascendis Pharma A/S's net income appears to be on an upward trend, with a most recent value of -$391.35 million in 2024, rising from -$35.77 million in 2015. The previous period was -$532.58 million in 2023. Find out what analysts predict for Ascendis Pharma A/S in the coming months.

What is Ascendis Pharma A/S's operating income?

Ascendis Pharma A/S's total operating income in 2024 was -$288.55 million, based on the following breakdown:

Total Gross Profit: $330.59 million
Total Operating Expenses: $619.14 million

How has Ascendis Pharma A/S revenue changed over the last 9 years?

Over the last 9 years, Ascendis Pharma A/S's total revenue changed from $8.82 million in 2015 to $376.40 million in 2024, a change of 4,167.4%.

How much debt does Ascendis Pharma A/S have?

Ascendis Pharma A/S's total liabilities were at $1.33 billion at the end of 2024, a 23.8% increase from 2023, and a 9,296.3% increase since 2016.

How much cash does Ascendis Pharma A/S have?

In the past 8 years, Ascendis Pharma A/S's cash and equivalents has ranged from $189.71 million in 2016 to $714.05 million in 2020, and is currently $579.18 million as of their latest financial filing in 2024.

How has Ascendis Pharma A/S's book value per share changed over the last 9 years?

Over the last 9 years, Ascendis Pharma A/S's book value per share changed from 0.00 in 2015 to -1.90 in 2024, a change of -189.6%.

Related Companies

This page (NASDAQ:ASND) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ascendis Pharma A/S (ASND) Financials

Frequently Asked Questions About Ascendis Pharma A/S's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ascendis Pharma A/S (ASND) Financials

Annual Income Statements for Ascendis Pharma A/S

Quarterly Income Statements for Ascendis Pharma A/S

Annual Cash Flow Statements for Ascendis Pharma A/S

Quarterly Cash Flow Statements for Ascendis Pharma A/S

Annual Balance Sheets for Ascendis Pharma A/S

Quarterly Balance Sheets for Ascendis Pharma A/S

Annual Metrics And Ratios for Ascendis Pharma A/S

Quarterly Metrics And Ratios for Ascendis Pharma A/S

Frequently Asked Questions About Ascendis Pharma A/S's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools